PURPOSE: One of the most relevant aspects in cell death regulation is the signalling of apoptosis by the serine/threonine kinases MAPKs. The aim of this study was to investigate the effects of TNF-alpha stimulation on MAPK activation, and the pro- or anti-apoptotic role of these kinases in LNCaP and PC3 cells. MATERIAL AND METHODS: Treatments were carried out using several TNF-alpha concentrations, as well as specific pharmacological inhibitors of MAPKs. Apoptosis rates were evaluated by DAPI staining and flow cytometry. MAPK phosphorylation/activation was measured by Western blot. RESULTS: TNF-alpha induced apoptosis in a dose-dependent manner in LNCaP but not in PC3 cells. The MAPK inhibitors revealed that the apoptotic rate in LNCaP cells increased significantly following p38 inhibition. The kinase inhibitors failed to cause changes in apoptosis in PC3 cells. CONCLUSIONS: The potentiation of apoptosis by p38 inhibition points to this kinase as a possible target for the treatment of androgen-dependent prostatic cancer.
PURPOSE: One of the most relevant aspects in cell death regulation is the signalling of apoptosis by the serine/threonine kinases MAPKs. The aim of this study was to investigate the effects of TNF-alpha stimulation on MAPK activation, and the pro- or anti-apoptotic role of these kinases in LNCaP and PC3 cells. MATERIAL AND METHODS: Treatments were carried out using several TNF-alpha concentrations, as well as specific pharmacological inhibitors of MAPKs. Apoptosis rates were evaluated by DAPI staining and flow cytometry. MAPK phosphorylation/activation was measured by Western blot. RESULTS:TNF-alpha induced apoptosis in a dose-dependent manner in LNCaP but not in PC3 cells. The MAPK inhibitors revealed that the apoptotic rate in LNCaP cells increased significantly following p38 inhibition. The kinase inhibitors failed to cause changes in apoptosis in PC3 cells. CONCLUSIONS: The potentiation of apoptosis by p38 inhibition points to this kinase as a possible target for the treatment of androgen-dependent prostatic cancer.
Authors: Timothy O Adekoya; Nikia Smith; Temilade Aladeniyi; Joe B Blumer; Xiaoxin L Chen; Ricardo M Richardson Journal: Carcinogenesis Date: 2019-12-31 Impact factor: 4.944
Authors: Beatriz Gil-Araujo; María-Val Toledo Lobo; María Gutiérrez-Salmerón; Julia Gutiérrez-Pitalúa; Santiago Ropero; Javier C Angulo; Antonio Chiloeches; Marina Lasa Journal: Mol Oncol Date: 2013-09-14 Impact factor: 6.603
Authors: Deborah A Ferrington; Heidi Roehrich; Angela A Chang; Craig W Huang; Marcela Maldonado; Wendy Bratten; Abrar A Rageh; Neal D Heuss; Dale S Gregerson; Elizabeth F Nelson; Ching Yuan Journal: PLoS One Date: 2013-01-24 Impact factor: 3.240